Docetaxel Kabi
Docetaxel – Taxane Chemotherapy Agent
Quick Facts About Docetaxel Kabi
Key Takeaways About Docetaxel Kabi
- Hospital-only chemotherapy: Docetaxel Kabi must be administered intravenously by qualified healthcare professionals in a hospital or clinic setting with appropriate monitoring facilities
- Premedication is essential: Corticosteroid premedication (typically dexamethasone) must be taken before each infusion to prevent fluid retention and severe allergic reactions
- Blood monitoring required: Complete blood counts must be checked before every cycle – treatment cannot proceed if neutrophils fall below 1,500 cells/mm³
- Multiple cancer indications: Effective against breast cancer, non-small cell lung cancer, hormone-refractory prostate cancer, gastric adenocarcinoma, and head and neck squamous cell carcinoma
- Pregnancy is contraindicated: Docetaxel is harmful to unborn babies – effective contraception must be used during treatment and for at least 6 months after the last dose
What Is Docetaxel Kabi and What Is It Used For?
Docetaxel Kabi is a cytotoxic chemotherapy medicine containing the active substance docetaxel, a semi-synthetic taxane derived from the needles of the European yew tree (Taxus baccata). It works by disrupting the normal function of microtubules inside cancer cells, preventing them from dividing and ultimately causing cell death.
Docetaxel belongs to the taxane family of chemotherapy drugs, which are among the most widely used and effective antineoplastic agents worldwide. The taxane class also includes paclitaxel and cabazitaxel. Docetaxel was first approved by the European Medicines Agency (EMA) in 1995 and has since become a cornerstone of modern oncology treatment protocols. Docetaxel Kabi is a generic formulation of docetaxel manufactured by Fresenius Kabi, which contains the same active substance as the original branded product.
The mechanism of action of docetaxel is well characterised. Normally, cells use structures called microtubules as part of their internal skeleton, which plays a critical role during cell division (mitosis). Docetaxel promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This abnormal stabilisation of microtubules prevents the cell from completing the process of division, leading to cell cycle arrest and programmed cell death (apoptosis). Because cancer cells divide more rapidly than most normal cells, they are disproportionately affected by docetaxel.
Docetaxel has been shown in preclinical studies to have approximately twice the binding affinity for tubulin compared to paclitaxel, another taxane chemotherapy agent. This higher potency translates into significant clinical activity across a broad range of solid tumour types. In vitro, docetaxel has demonstrated cytotoxic effects against tumour cell lines from breast, ovarian, lung, colon, and prostate cancers, as well as leukaemia and melanoma cell lines.
Approved Indications
Docetaxel Kabi is approved for the treatment of the following cancers, typically in combination with other anticancer agents:
- Breast cancer: Both early-stage (adjuvant therapy after surgery) and locally advanced or metastatic breast cancer. In the adjuvant setting, docetaxel is commonly combined with doxorubicin and cyclophosphamide (TAC regimen). For metastatic disease, it may be given as monotherapy or combined with capecitabine or trastuzumab (for HER2-positive tumours).
- Non-small cell lung cancer (NSCLC): As first-line treatment in combination with cisplatin for patients with unresectable, locally advanced or metastatic disease, or as monotherapy in patients who have failed prior platinum-based chemotherapy.
- Hormone-refractory prostate cancer: In combination with prednisone or prednisolone for men with metastatic castration-resistant prostate cancer (mCRPC). The landmark TAX 327 trial demonstrated a significant survival benefit in this population.
- Gastric adenocarcinoma: In combination with cisplatin and 5-fluorouracil for patients with metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction, who have not received prior chemotherapy.
- Head and neck squamous cell carcinoma: As induction chemotherapy in combination with cisplatin and 5-fluorouracil (TPF regimen) for patients with locally advanced disease before definitive radiotherapy or chemoradiotherapy.
Docetaxel Kabi must only be prescribed and administered under the supervision of a physician who is experienced in the use of cancer chemotherapy. Appropriate facilities for the management of potential complications, including severe hypersensitivity reactions and neutropenic complications, must be readily available.
What Should You Know Before Taking Docetaxel Kabi?
Before starting Docetaxel Kabi, your oncologist will evaluate your overall health, perform blood tests, and review your medical history. Certain conditions or medications may make Docetaxel Kabi unsuitable or require special monitoring.
A thorough pre-treatment assessment is essential before beginning docetaxel therapy. This assessment serves to identify patients who may be at increased risk of serious adverse effects and to establish baseline values for monitoring during treatment. Your oncology team will take into account your general fitness, organ function, and any concurrent medical conditions before making a treatment decision.
Contraindications
Docetaxel Kabi must not be given in the following situations:
- Hypersensitivity: Known severe allergy to docetaxel, other taxanes, or polysorbate 80 (an excipient in the formulation). Severe hypersensitivity reactions, including fatal anaphylaxis, have been reported in clinical practice.
- Neutropenia: Baseline neutrophil count below 1,500 cells/mm³. Docetaxel causes significant myelosuppression, and starting treatment with already-low neutrophil counts dramatically increases the risk of severe neutropenic complications.
- Severe hepatic impairment: Patients with serum bilirubin exceeding the upper limit of normal, or ALT and/or AST greater than 1.5 times the upper limit of normal combined with alkaline phosphatase greater than 2.5 times the upper limit of normal. Docetaxel is primarily metabolised by the liver, and impaired hepatic function significantly increases systemic exposure and the risk of severe toxicity, including treatment-related death.
- Pregnancy and breastfeeding: Docetaxel is embryotoxic and fetotoxic. It must not be used during pregnancy or breastfeeding.
Warnings and Precautions
Several important warnings apply to treatment with Docetaxel Kabi. Your oncology team will monitor you closely for the following risks:
Premedication requirement: All patients must receive oral corticosteroid premedication before each docetaxel infusion. The standard regimen is oral dexamethasone 16 mg per day (8 mg twice daily) for 3 days, starting 1 day before the docetaxel infusion. This is mandatory to reduce the incidence and severity of fluid retention (oedema) and hypersensitivity reactions. Without premedication, the risk of severe fluid retention and potentially fatal allergic reactions is substantially increased.
Haematological toxicity: Neutropenia is the most frequent and dose-limiting toxicity of docetaxel. The neutrophil nadir typically occurs around day 7 of each cycle, with recovery by day 15–21. Frequent monitoring of blood counts is essential, and dose reductions or treatment delays may be necessary if neutrophil counts are inadequate at the start of a cycle. Granulocyte colony-stimulating factor (G-CSF) prophylaxis may be considered for patients at high risk of febrile neutropenia, in accordance with current ESMO and ASCO guidelines.
Hypersensitivity reactions: Severe reactions characterised by generalised rash or erythema, hypotension, bronchospasm, or very rarely fatal anaphylaxis have been reported. Patients should be closely observed during the first and second infusions, as the risk of hypersensitivity is highest during initial exposure. If a severe reaction occurs, docetaxel must be discontinued immediately, and appropriate emergency treatment must be administered. Patients who have experienced a severe hypersensitivity reaction should not be re-challenged with docetaxel.
Fluid retention: Docetaxel commonly causes fluid retention manifesting as peripheral oedema, pleural effusions, pericardial effusions, or ascites. The risk increases with cumulative dose, becoming more frequent and severe after approximately 400 mg/m² cumulative exposure. Corticosteroid premedication substantially reduces but does not eliminate this risk. In clinical trials, severe fluid retention requiring urgent treatment occurred in approximately 6.5% of patients receiving standard premedication.
Hepatic impairment: Patients with elevated liver function tests should be monitored with particular caution, as they are at higher risk for severe toxicity. Liver function tests (bilirubin, transaminases, alkaline phosphatase) should be obtained before each cycle of therapy. Patients with bilirubin above the upper limit of normal and/or ALT/AST above 3.5 times the upper limit of normal in conjunction with alkaline phosphatase above 6 times the upper limit of normal have a significantly increased risk of grade 4 toxicity and treatment-related death.
Peripheral neuropathy: Docetaxel may cause peripheral sensory neuropathy, characterised by numbness, tingling, or pain in the hands and feet. The incidence increases with cumulative dose. If severe symptoms develop (grade 3 or above), the dose should be reduced. If symptoms persist despite dose reduction, treatment discontinuation should be considered. Some degree of neuropathy may persist for months or years after treatment completion.
Cutaneous reactions: Skin reactions including localised eruptions on the extremities, severe skin toxicity such as desquamation, and in very rare cases, bullous eruptions have been reported. Nail toxicity, including nail discolouration, onycholysis (separation of the nail from the nail bed), and pain, is common. Cooling of the hands and feet during infusion may help reduce nail and skin toxicity in some patients.
Docetaxel Kabi should not be given if the neutrophil count is below 1,500 cells/mm³. Patients developing febrile neutropenia (fever with low neutrophils) require urgent medical attention, including hospitalisation and intravenous antibiotics. Febrile neutropenia can be life-threatening if not treated promptly. Contact your oncology team immediately if you develop a temperature of 38°C or above at any time during treatment.
Pregnancy and Breastfeeding
Docetaxel Kabi is classified as a pregnancy category D medication. Animal studies have demonstrated clear evidence of embryotoxicity and fetotoxicity, and the drug's mechanism of action (disrupting cell division) poses a direct risk to a developing foetus. There are no adequate controlled studies in pregnant women, but based on its pharmacological activity, docetaxel would be expected to cause birth defects when administered during pregnancy.
Women of childbearing potential must use effective contraception during treatment with docetaxel and for at least 6 months following the last dose. A pregnancy test should be performed before starting treatment. If pregnancy occurs during treatment, the patient must be informed immediately of the potential hazard to the foetus, and appropriate counselling regarding the risks should be provided.
Male patients are also advised to use effective contraception during treatment and for at least 6 months after the final dose. Men should also seek advice about sperm preservation (cryopreservation) before starting treatment, as docetaxel may impair fertility through direct effects on spermatogenesis.
Breastfeeding is contraindicated during docetaxel therapy. It is not known whether docetaxel is excreted in human breast milk, but given the potential for serious adverse reactions in nursing infants, breastfeeding must be discontinued before starting treatment and must not be resumed until at least 6 weeks after the last dose.
How Does Docetaxel Kabi Interact with Other Drugs?
Docetaxel is primarily metabolised by the cytochrome P450 CYP3A4 enzyme system. Drugs that inhibit or induce this enzyme can significantly alter docetaxel blood levels, increasing toxicity or reducing effectiveness.
Drug interactions are a major consideration with docetaxel therapy. Because the drug is extensively metabolised by CYP3A4 in the liver, co-administration of drugs that affect this enzyme pathway can have clinically significant consequences. Your oncologist will carefully review all medications, including over-the-counter drugs, herbal supplements, and complementary medicines, before starting treatment.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of drugs that induce, inhibit, or are metabolised by CYP3A4. The interaction potential is considered clinically relevant because docetaxel has a relatively narrow therapeutic index – meaning the difference between an effective dose and a toxic dose is small. A pharmacokinetic study with ketoconazole demonstrated that CYP3A4 inhibition can decrease docetaxel clearance by approximately 49%, resulting in a 2.2-fold increase in systemic exposure.
Major Interactions
The following drug interactions are considered clinically significant and may require dose adjustment, alternative medication, or enhanced monitoring:
| Interacting Drug | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Ketoconazole | Strong CYP3A4 inhibitor | Increases docetaxel exposure by approximately 2.2-fold | Avoid concomitant use; if unavoidable, reduce docetaxel dose by 50% |
| Itraconazole | Strong CYP3A4 inhibitor | Significantly increased docetaxel levels and toxicity risk | Avoid concomitant use |
| Clarithromycin | Strong CYP3A4 inhibitor | Increased docetaxel exposure and toxicity | Use alternative antibiotic (e.g. azithromycin) |
| Rifampicin | Strong CYP3A4 inducer | Decreased docetaxel exposure by approximately 80% | Avoid concomitant use; reduced anticancer efficacy expected |
| Phenytoin / Carbamazepine | Strong CYP3A4 inducers | Significantly reduced docetaxel levels | Consider alternative anticonvulsant (e.g. levetiracetam) |
| Doxorubicin | Pharmacokinetic interaction | Docetaxel increases doxorubicin clearance when used in combination | Monitor closely; used in established combination regimens (TAC) |
Minor Interactions
The following interactions are of lesser clinical significance but should still be communicated to your healthcare team:
- Moderate CYP3A4 inhibitors (e.g. fluconazole, erythromycin, verapamil, diltiazem): May moderately increase docetaxel exposure. Close monitoring for toxicity signs is recommended.
- Grapefruit juice: Contains natural CYP3A4 inhibitors (furanocoumarins). Patients should avoid grapefruit and grapefruit juice during treatment, as it may increase docetaxel levels unpredictably.
- St. John's Wort (Hypericum perforatum): A potent CYP3A4 inducer that may reduce docetaxel efficacy. Must be avoided during treatment and for at least two weeks before the first infusion.
- Cisplatin: When used in combination, no clinically significant pharmacokinetic interaction has been observed. Renal function should be carefully monitored due to the nephrotoxic potential of cisplatin.
- Capecitabine: No clinically relevant pharmacokinetic interaction. Combination is used in established regimens for breast and gastric cancer.
- Trastuzumab: No pharmacokinetic interaction observed. The combination is standard for HER2-positive breast cancer, but cardiac function should be monitored closely as both agents may affect the heart.
What Is the Correct Dosage of Docetaxel Kabi?
Docetaxel Kabi is administered as a one-hour intravenous infusion. The dose is calculated based on body surface area (BSA) in mg/m² and varies depending on the type of cancer, treatment regimen, and the patient's general condition. Treatment is typically given every 3 weeks (21-day cycles).
The dosage of Docetaxel Kabi is individualised for each patient based on the type and stage of cancer being treated, the specific chemotherapy protocol being used, the patient's body surface area, and their overall medical condition. All doses are calculated in milligrams per square metre of body surface area (mg/m²). The decision on the appropriate dose and schedule is made by an experienced oncologist.
Before each infusion cycle, a complete blood count must be performed to confirm that neutrophil and platelet levels are adequate. Treatment must be delayed if the neutrophil count is below 1,500 cells/mm³. Liver function tests should also be checked prior to each cycle, as hepatic impairment can significantly increase the risk of severe toxicity.
| Cancer Type | Docetaxel Dose | Combination Agents | Cycle Length |
|---|---|---|---|
| Breast cancer (adjuvant) | 75 mg/m² | Doxorubicin + Cyclophosphamide (TAC) | Every 3 weeks x 6 cycles |
| Breast cancer (metastatic, mono) | 100 mg/m² | None (monotherapy) | Every 3 weeks |
| Breast cancer (with capecitabine) | 75 mg/m² | Capecitabine 1250 mg/m² twice daily | Every 3 weeks |
| NSCLC (first-line) | 75 mg/m² | Cisplatin 75 mg/m² | Every 3 weeks |
| NSCLC (second-line, mono) | 75 mg/m² | None (monotherapy) | Every 3 weeks |
| Prostate cancer (mCRPC) | 75 mg/m² | Prednisone 5 mg twice daily (continuous) | Every 3 weeks x 10 cycles |
| Gastric adenocarcinoma | 75 mg/m² | Cisplatin + 5-fluorouracil | Every 3 weeks |
| Head and neck SCC (induction) | 75 mg/m² | Cisplatin + 5-fluorouracil (TPF) | Every 3 weeks x 4 cycles |
Adults
For adult patients, the recommended dose ranges from 75 to 100 mg/m², depending on the indication and regimen. Monotherapy for metastatic breast cancer typically uses the higher dose of 100 mg/m², while most combination regimens use 75 mg/m² to balance efficacy with tolerability when multiple cytotoxic agents are combined.
Prior to each infusion, patients must receive their prescribed corticosteroid premedication (typically dexamethasone 8 mg twice daily for 3 days, beginning the day before the infusion). The infusion is prepared by diluting the concentrate into an appropriate intravenous solution (0.9% sodium chloride or 5% glucose) and is administered over approximately one hour through a controlled intravenous drip. Patients should be monitored during and after the infusion for signs of hypersensitivity or other acute reactions.
Children
The safety and efficacy of Docetaxel Kabi in children and adolescents below 18 years of age have not been established. Docetaxel is not approved for paediatric use, and there is insufficient data to recommend a dose in this population. A phase II study conducted in paediatric patients with relapsed or refractory solid tumours did not demonstrate sufficient activity to support further development in this age group. Any use of docetaxel in paediatric patients would be considered off-label and would only occur within the context of a clinical trial.
Elderly
No specific dose adjustment is routinely recommended for elderly patients based on age alone. However, elderly patients may be more susceptible to certain adverse effects, particularly neutropenia, fatigue, and peripheral neuropathy. Population pharmacokinetic analyses have not identified age as a significant factor influencing docetaxel clearance. Nevertheless, careful assessment of renal and hepatic function, performance status, and comorbidities is essential when determining the appropriate dose for older patients. Geriatric oncology assessments (such as the Comprehensive Geriatric Assessment) may be useful in guiding treatment decisions for patients aged 70 years and above.
Dose Adjustments for Toxicity
Dose reductions are mandated based on the type and severity of toxicity experienced during treatment. The following adjustments are standard:
- Febrile neutropenia or neutrophils <500/mm³ for more than 1 week: Reduce dose from 100 to 75 mg/m², or from 75 to 60 mg/m². If the problem recurs at the reduced dose, discontinue treatment or further reduce to 60 mg/m².
- Severe cutaneous reactions: Reduce dose. If severe skin toxicity persists, discontinue treatment.
- Severe peripheral neuropathy (grade 3 or higher): Reduce dose. If symptoms do not improve, consider discontinuation.
- Hepatic impairment: Patients with elevated bilirubin and/or transaminases combined with elevated alkaline phosphatase should not receive docetaxel.
- Severe stomatitis (grade 3-4): Reduce dose. Consider prophylactic measures for subsequent cycles.
Missed Dose
Because Docetaxel Kabi is administered in a hospital setting by healthcare professionals on a scheduled cycle, the concept of a "missed dose" in the traditional sense does not apply. However, treatment cycles may be delayed if blood counts have not recovered adequately or if the patient is experiencing significant side effects from the previous cycle. Delays of one to two weeks are common and do not generally compromise treatment efficacy. Your oncologist will determine the appropriate timing for each subsequent cycle based on your clinical condition and laboratory results.
Overdose
There is no known specific antidote for docetaxel overdose. In the event of an overdose, the patient should be admitted to a specialist unit and vital signs closely monitored. The primary anticipated complications of overdose are bone marrow suppression (severe neutropenia and thrombocytopenia), peripheral neurotoxicity, and mucositis. Treatment is supportive and symptomatic, with granulocyte colony-stimulating factor (G-CSF) to manage neutropenia and other measures as clinically indicated. Early consultation with a clinical toxicologist or poison control centre is advised.
What Are the Side Effects of Docetaxel Kabi?
Like all chemotherapy medicines, Docetaxel Kabi can cause side effects, although not everybody gets them. The most common side effects include neutropenia, anaemia, hair loss, nausea, fatigue, fluid retention, and peripheral neuropathy. Most side effects are reversible after treatment is completed.
The side effect profile of docetaxel has been extensively characterised through decades of clinical trials and post-marketing surveillance involving hundreds of thousands of patients worldwide. Understanding potential side effects is important so that patients and caregivers can recognise them early and seek appropriate medical attention. Your oncology team will discuss expected side effects before treatment begins and provide guidance on when to contact them.
It is important to note that the occurrence and severity of side effects can vary considerably between patients. Factors that influence toxicity include the dose used, the specific combination regimen, the number of prior treatments, the patient's age and general health, and the presence of comorbidities. Many side effects are manageable with supportive care, and your oncology team has a range of medications and interventions available to help mitigate symptoms.
The frequency of side effects is classified according to the following internationally standardised categories:
Very Common (affects more than 1 in 10 patients)
- Neutropenia – Decrease in white blood cells (neutrophils), which increases infection risk. This is the most common and potentially most serious side effect, occurring in up to 96% of patients.
- Anaemia – Decrease in red blood cells causing fatigue, shortness of breath, and pallor
- Thrombocytopenia – Decrease in platelets, increasing the risk of bleeding and bruising
- Alopecia (hair loss) – Usually complete and reversible after treatment; hair typically regrows within 3–6 months
- Nausea and vomiting – Usually manageable with antiemetic medications
- Diarrhoea – May require anti-diarrhoeal medications and fluid replacement
- Stomatitis (mouth sores) – Inflammation and ulceration of the oral mucosa
- Fatigue and asthenia – Generalised tiredness and weakness, often cumulative over multiple cycles
- Fluid retention (oedema) – Peripheral swelling, weight gain; reduced by corticosteroid premedication
- Peripheral neuropathy – Numbness, tingling, or pain in hands and feet
- Myalgia and arthralgia – Muscle and joint pain, typically peaking 2–3 days after infusion
- Nail changes – Discolouration, brittleness, or nail loss (onycholysis)
- Skin reactions – Rash, erythema, pruritus, or skin dryness
Common (affects 1 to 10 in 100 patients)
- Febrile neutropenia – Fever combined with very low neutrophil counts; requires urgent medical attention
- Infections – Including oral candidiasis, urinary tract infections, and respiratory infections
- Hypersensitivity reactions – Flushing, rash, chest tightness, back pain, dyspnoea, or fever during or shortly after infusion
- Anorexia (loss of appetite) – May contribute to weight loss and malnutrition
- Taste disturbance (dysgeusia) – Altered or metallic taste sensation
- Constipation – May be exacerbated by antiemetic medications
- Cardiac arrhythmias – Including tachycardia
- Elevated liver enzymes – Transient increases in ALT, AST, and bilirubin
- Injection site reactions – Swelling, pain, or erythema at the infusion site
Uncommon (affects 1 to 10 in 1,000 patients)
- Heart failure – Particularly when combined with trastuzumab or anthracyclines
- Pleural effusion – Accumulation of fluid around the lungs
- Pericardial effusion – Fluid accumulation around the heart
- Severe skin reactions – Including erythema multiforme and very rarely Stevens-Johnson syndrome
- Interstitial pneumonitis / pulmonary fibrosis – Inflammation of lung tissue, which can be serious
- Intestinal obstruction – Potentially serious gastrointestinal complication
Rare (affects fewer than 1 in 1,000 patients)
- Anaphylaxis – Severe, potentially life-threatening allergic reaction; very rarely fatal despite premedication
- Disseminated intravascular coagulation (DIC) – Serious clotting disorder
- Acute myeloid leukaemia / myelodysplastic syndrome – Secondary malignancy associated with long-term use, particularly in combination regimens
- Colitis / enterocolitis – Including neutropenic enterocolitis (typhlitis)
- Severe hepatotoxicity – Including very rare cases of fatal hepatitis
- Radiation recall dermatitis – Recurrence of skin reactions at sites of prior radiation therapy
- Persistent alopecia – Very rare cases of persistent hair loss reported post-marketing
Contact your oncology team or seek emergency care immediately if you experience: fever above 38°C or chills (possible signs of neutropenic infection); severe breathlessness or chest pain; severe diarrhoea (more than 6 episodes in 24 hours); signs of allergic reaction such as swelling of face, tongue or throat, difficulty breathing, or widespread rash; unusual bleeding or bruising; or severe abdominal pain.
How Should You Store Docetaxel Kabi?
Docetaxel Kabi is stored and handled by hospital pharmacy staff. The unopened vials should be stored below 25°C and protected from light. Once diluted for infusion, the solution must be used within a limited timeframe.
As Docetaxel Kabi is a hospital-administered medicine, patients do not typically need to store it at home. However, understanding the storage requirements is important for ensuring the integrity and safety of the medication.
Unopened vials: Store below 25°C. Do not freeze. Keep the vial in the outer carton to protect from light. When stored according to these conditions, the shelf life is as stated on the packaging (typically 2–3 years from the date of manufacture).
After opening / dilution: Once the vial is opened, the concentrate should be used immediately. After dilution in an appropriate infusion solution (0.9% sodium chloride or 5% glucose solution), the prepared infusion should be used within 6 hours when stored at room temperature (below 25°C), or within 48 hours when stored in a refrigerator (2–8°C). From a microbiological point of view, immediate use after preparation is recommended.
Handling precautions: As with all cytotoxic medicines, Docetaxel Kabi must be handled with care. Healthcare professionals involved in the preparation and administration of docetaxel should follow institutional guidelines for safe handling of cytotoxic drugs, including the use of protective gloves, gowns, and safety goggles. Pregnant staff should not handle cytotoxic agents. Any spills should be managed according to local hazardous material procedures.
Disposal: Any unused medicine or waste material should be disposed of in accordance with local requirements for cytotoxic waste. Docetaxel should never be disposed of via household waste or wastewater systems.
What Does Docetaxel Kabi Contain?
Docetaxel Kabi contains the active substance docetaxel as a concentrate for solution for infusion. Each millilitre of concentrate contains 20 mg of docetaxel (anhydrous). The formulation also includes polysorbate 80 and ethanol as excipients.
Understanding the composition of Docetaxel Kabi is important, particularly for patients with known allergies or sensitivities to specific excipients.
Active substance: Docetaxel (as docetaxel trihydrate). Docetaxel is a semi-synthetic taxane produced from 10-deacetylbaccatin III, a natural precursor extracted from the needles of the European yew tree (Taxus baccata). The molecular formula of docetaxel trihydrate is C43H53NO14·3H2O, with a molecular weight of approximately 861.9 g/mol.
Excipients:
- Polysorbate 80: A non-ionic surfactant used to improve the solubility of docetaxel. Polysorbate 80 is a known potential allergen and can cause hypersensitivity reactions in rare cases. Patients with a history of severe reactions to polysorbate 80 should not receive docetaxel.
- Anhydrous ethanol (alcohol): Used as a co-solvent in the formulation. Each vial contains a clinically relevant amount of alcohol. This should be taken into consideration for patients with alcohol dependence, liver disease, epilepsy, or for pregnant and breastfeeding women. The alcohol content may also affect patients taking certain medications, such as metronidazole or disulfiram.
Appearance: The concentrate is a clear, viscous, yellow to brownish-yellow solution. Before administration, it must be diluted with the appropriate infusion solution. The diluted solution should be inspected visually for particulate matter and discolouration prior to administration, and should not be used if particles are visible or if the solution appears abnormally coloured.
Docetaxel Kabi contains ethanol (alcohol). This may be of relevance for patients with liver disease, alcoholism, epilepsy, brain injury or disease, as well as for children and pregnant women. The amount of alcohol in this medicine may modify the effects of other medicines and may impair driving ability or the use of machines.
Frequently Asked Questions About Docetaxel Kabi
Docetaxel Kabi is a chemotherapy medicine used to treat several types of cancer. Its primary indications include breast cancer (both early-stage as adjuvant therapy and advanced/metastatic disease), non-small cell lung cancer, hormone-refractory (castration-resistant) prostate cancer, gastric adenocarcinoma, and head and neck squamous cell carcinoma. It is usually given in combination with other anticancer medicines, and the specific regimen depends on the cancer type and stage.
A typical Docetaxel Kabi infusion takes approximately one hour. However, you should expect to spend longer at the clinic or hospital, as preparation time, monitoring during the infusion, and a post-infusion observation period are all standard practice. In total, each treatment session may last 2–4 hours. Corticosteroid premedication must be started the day before the infusion and continued for 3 days.
Hair loss (alopecia) is a very common side effect of docetaxel, occurring in the majority of patients. Hair loss typically begins 2–3 weeks after the first infusion and is usually complete. The good news is that hair loss from docetaxel is almost always reversible, and hair typically begins to regrow within 3–6 months after the last treatment cycle. In very rare post-marketing cases, persistent or permanent hair loss has been reported. Scalp cooling caps may reduce the severity of hair loss for some patients.
Dexamethasone (a corticosteroid) is required as premedication before each docetaxel infusion to prevent two significant complications: fluid retention (oedema) and hypersensitivity (allergic) reactions. Without corticosteroid premedication, the risk of severe fluid retention and life-threatening allergic reactions is substantially higher. The standard regimen is dexamethasone 8 mg twice daily for 3 days, starting the day before the infusion. It is critical to take this medication exactly as prescribed – do not skip doses.
Docetaxel Kabi may impair your ability to drive or operate machinery, both due to the drug itself and its alcohol content. Fatigue, nausea, and peripheral neuropathy (affecting sensation in hands and feet) are common side effects that may affect your ability to drive safely. The alcohol content in the formulation may also cause temporary impairment. You should not drive or operate machinery if you feel unwell, drowsy, or notice any impairment in your coordination or reaction times after treatment.
Before each cycle of Docetaxel Kabi, you will need a complete blood count (CBC) to check your neutrophil count and platelet levels. Treatment cannot proceed if your neutrophil count is below 1,500 cells/mm³. Your oncologist will also monitor liver function tests (bilirubin, ALT/AST, alkaline phosphatase) regularly, as docetaxel is metabolised by the liver and hepatic impairment increases the risk of severe toxicity. Additional tests may include renal function, especially if docetaxel is combined with cisplatin.
References
- European Medicines Agency (EMA). Docetaxel – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed December 2025.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (TAX 327). N Engl J Med. 2004;351(15):1502-1512.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer (BCIRG 001). N Engl J Med. 2005;352(22):2302-2313.
- Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323). N Engl J Med. 2007;357(17):1695-1704.
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer (V325). J Clin Oncol. 2006;24(31):4991-4997.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Available at: www.nccn.org. Accessed December 2025.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines. Available at: www.esmo.org. Accessed December 2025.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Docetaxel monograph. Available at: bnf.nice.org.uk. Accessed December 2025.
- Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13(1):49-59.
Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, comprising board-certified specialists in oncology and clinical pharmacology. Our editorial process follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, ESMO, and NCCN.
Written by licensed physicians with expertise in oncology and clinical pharmacology. All medical claims are supported by peer-reviewed evidence at Evidence Level 1A.
Independently reviewed by the iMedic Medical Review Board. Reviewed against EMA SmPC, FDA prescribing information, ESMO guidelines, and BNF monograph.
Conflict of Interest: None. iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent.
Last medical review:
Next scheduled review: